Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.N Engl J Med. 2016; 375: 2246-2254
- Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.N Engl J Med. 2021; 385: 683-694
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol. 2009; 27: 5794-5799
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.J Clin Oncol. 2002; 20: 289-296
- Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.J Clin Oncol. 2005; 23: 832-841
- Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group.Clin Cancer Res. 2011; 17: 5443-5450
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.Lancet Oncol. 2013; 14: 141-148
- Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria.Cancer. 2013; 119: 2999-3006
- Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.Eur Urol. 2014; 65: 577-584
- Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.Mol Aspects Med. 2011; 32: 88-111
- Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal.Cell. 2018; 173: 581-594.e12
- Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.Cancer Chemother Pharmacol. 2014; 73: 151-161
- Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial.Clin Cancer Res. 2010; 16: 4853-4863
- Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.J Clin Oncol. 2009; 27: 3312-3318
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.Ann Oncol. 2012; 23: 46-52
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.Lancet Oncol. 2012; 13: 827-837
- Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC).J Clin Oncol. 2011; 29: 4553
- Cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): current knowledge and potential uses.3 (1). Kidney Cancer, 2019: 7-13
- Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.Nat Med. 2020; 26: 1041-1043
- Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma.Eur Urol. 2017; 72: 557-564
- Matched molecular profiling of cell-free dna and tumor tissue in patients with advanced clear cell renal cell carcinoma.JCO Precis Oncol. 2022; 6: e2200012
Yamamoto Y, Uemura M, Nakano K, et al. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. 2018.
- Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients.Clinica Chim Acta. 2016/1//2016; 452: 109-119https://doi.org/10.1016/j.cca.2015.11.009
- Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer.Dis Markers. 2016; 2016https://doi.org/10.1155/2016/3693096
- Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade.Urology. 2014; 83 (256.e9-256.e14)
- Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.Nat Rev Mol Cell Biol. 2019; 20: 5-20
- Accurate molecular classification of kidney cancer subtypes using microRNA signature.Eur Urol. 2011; 59: 721-730
- miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation.J Urol. 2011; 186: 1077-1083
- Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.Clinica Chim Acta. 2013; 416: 5-10
- Validation in an independent cohort of MiR-122, MiR-1271, and MiR-15b as urinary biomarkers for the potential early diagnosis of clear cell renal cell carcinoma.Cancers. 2022; 14: 1112
- Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.Urol Oncol Semin Original Invest. 2013; 31: 493-498
- Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.PLoS One. 2010; 5https://doi.org/10.1371/journal.pone.0010715
- What does PD-L1 positive or negative mean?.J Exp Med. 2016; 213: 2835-2840
- Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med. 2015; 373: 1803-1813
- Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med. 2018; 378: 1277-1290
- Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2019; 380: 1116-1127
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.Lancet. 2019; 393: 2404-2415
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.Nat Med. 2020; 26: 1733-1741
- Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.Lancet Oncol. 2018; 19: 1688-1698
- ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma.Eur Urol. 2014; 66: 77-84
- Clear cell type A and B molecular subtypes in metastatic clear cell renal cell carcinoma: tumor heterogeneity and aggressiveness.Eur Urol. 2017; 71: 979-985
- A multigene signature based on cell cycle proliferation improves prediction of mortality within 5 yr of radical nephrectomy for renal cell carcinoma.Eur Urol. 2018; 73: 763-769
- Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns.Genes & Cancer. 2010; 1: 152-163
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.Genome Biol. 2016; 17: 231
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.Nat Med. 2020; 26: 909-918
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Science. 2018; 359: 801-806
- Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma.JAMA Oncol. 2019; 5: 1631-1633
- PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.Nat Commun. 2020; 11: 2135
- A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.Nat Commun. 2020; 11: 4168
- Immune checkpoint blockade in renal cell carcinoma.J Surg Oncol. 2021; 123: 739-750
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Nat Med. 2018; 24: 749-757
- Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma.Nat Rev Clin Oncol. 2021; 18: 199-214
- Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial.Cancer Discov. 2019; 9: 510-525
- A targetable myeloid inflammatory state governs disease recurrence in clear cell renal cell carcinoma.Cancer Discov. 2022; https://doi.org/10.1158/2159-8290.CD-21-0925
Article info
Footnotes
Funding: This was not funded.
Identification
Copyright
© 2022 Published by Elsevier Inc.
